anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: described is a pharmaceutical composition containing Enhol peptide or its functional fragment, functional homolog or functional structural analogue with conservative amino acid substitutes, and a pharmaceutically acceptable carrier for treatment and prevention of a pathophysiological state associated with excessive body weight. Offered are methods of treating and preventing the pathophysiological state referred to body weight homeostasis, including the introduction to an individual of a therapeutically effective amount of the described pharmaceutical composition. Presented are methods for improving or reducing insulin resistance in an individual, relieving or treating diabetes symptoms in an individual, preventing or delaying obesity in an individual, including the introduction to an individual of a therapeutically effective amount of Enhol peptide or its functional fragment, functional homolog or functional structural analogue with conservative amino acid substitutes. ^ EFFECT: invention can be used as a therapeutic or diagnostic modalities in hypercholesterolemia, hypertriglyceridemia, insulin resistance, obesity, diabetes or energy imbalance. ^ 11 cl, 23 dwg, 3 tbl, 25 ex
This group of patients will not receive intraoperative intercostal nerve block with 0.5% ropivacaine. After completing lung surgery, fully exposing the lateral and posterior chest wall. From the inside view of the chest cavity, the intercostal nerve enters the correlated intercostal space between the posterior intercostal membrane and the parietal pleura. The needle of the 1ml syringe was held with a thoracoscopic ovale forceps and the target intercostal nerves were confirmed. Inject physiologic saline(1ml) into the target nerve.
Children consume biofortified maize that has been traditionally bred to have higher amounts of iron and zinc. Children consume the biofortified maize via 10-15 tortillas a day for 3 days.
A pharmaceutical composition containing Interleukin-27, Il-27-Fc fusion protein and mutant thereof is provided to efficiently inhibit production of IL-17 and increase production of IFN-gamma by promoting differentiation of Th-1 in order to treat and prevent autoimmune diseases. A pharmaceutical composition for treatment and prevention of autoimmune diseases comprises Interleukin-27, Il-27-Fc fusion protein and mutant thereof. The Interleukin-27 is human-derived proteins. The pharmaceutical composition contains Il-27-Fc fusion protein wherein carboxyl terminal of the Interleukin-27 is coupled with amino terminal of immunoglobulin Fc and peptide. The immunoglobulin Fc is derived from one selected from the group consisting of IgG, IgA, IgM, IgE and IgD. The immunoglobulin Fc has a hinge site which can has one or more cysteins. The autoimmune diseases represent systemic lupus erythematosus, Sjogren syndrome, Hashimoto thyroiditis, rheumatoid arthritis, polymyositis, scleroderma, Addison disease, vitiligo, pernicious anemia, glomerulonephritis or pulmonary fibrosis.
Estradiol vaginal inserts USP, 10 mcg are white to off-white, round, film-coated, unscored, biconvex inserts containing 10.3 mcg of estradiol hemihydrate, USP equivalent to 10 mcg of estradiol. Each 10 mcg estradiol vaginal insert contains the following excipients: corn starch, hypromellose, lactose monohydrate, magnesium stearate, and polyethylene glycol. Each estradiol vaginal insert is 6 mm in diameter and is placed in a disposable applicator. Each insert-filled applicator is packaged separately in a blister pack. Estradiol vaginal inserts are used intravaginally. When the insert comes in contact with the vaginal mucosa, estradiol is released into the vagina.

Estradiol hemihydrate, USP is white to practically white crystals or powder and chemically described as estra1,3,5 (10)-triene-3,17β-diol, hydrate (2:1).

The structural formula is:

C18H24O2.1/2 H2O M.W. 281.4 (Estradiol hemihydrate, USP)

FDA approved dissolution test specifications differ from USP.
This prospective. randomized, double-blind. placebo-controlled release study will enroll approximately 300 healthy adults 18 to 49 years of age (not yet reached their 50th birthday). Eligible subjects will be randomly assigned in a 4:1 fashion to receive a single dose of bivalent vaccine or placebo by intranasal spray. Randomization will be stratified by site. This study will be conducted at 2 sites in the United States of America. Each subject will receive 1 dose of investigational product on Day 1. The duration of study participation for each subject is the time from study vaccination through 180 days after study vaccination.
OBJECTIVE: This study aims to reveal the importance of tertiary lymphoid structures (TLS) in transurethral resection of bladder tumor (TURBT) materials with a practical and applicable method in which the effect of a certain threshold value on survival and treatment response can be implicated.
METHODS: TURBT materials that had not previously received any treatment (chemotherapy, radiotherapy, or immunotherapy) and were diagnosed for the first time at Mardin Training and Research Hospital between 2014 and 2022 were included in the study. The maximum TLS per 4× magnification field (field diameter: 4.5 mm) was recorded. Grouping and statistical analysis of the TLS number were performed using threshold values of "≥1", "≥2", and "≥3".
RESULTS: TLSs were more frequently found in high-grade tumors (P = 0.008) and showed a strong association with stage progression (P < 0.001). It was also significantly associated with many adverse histopathological parameters. Conversely, high TLS (≥1, ≥2, and ≥3) appeared to be associated with fewer recurrences (P = 0.032, P = 0.001, and P = 0.018, respectively), and cases with higher TLS showed longer recurrence-free survival (P = 0.089, P = 0.023, P = 0.037, respectively). TLS≥3 was found to be an independent parameter that was associated with favorable RFS (P = 0.019, HR = 0.401), and multifocality was found to be an independent risk factor for RFS (P = 0.023, HR = 2.302).
CONCLUSION: This study is the first to demonstrate the relationship between the presence and specific thresholds of TLS in TURBT materials with prognostic parameters. Including this information in the routine pathological examination of TURBT materials will allow a more accurate approach to treatment and follow-up, especially in patients with non-muscle invasive bladder cancer (NMIBC).
BACKGROUND: Oral diseases are a significant global public health challenge. Current evidence indicates that several chronic conditions are individually associated with tooth loss. People are living with more than one chronic condition, known as multimorbidity (MM). Considering the common risk factors for oral and chronic diseases, this study aimed to evaluate the association between MM and tooth loss in the Chilean population.
METHODS: Cross-sectional study with secondary data from the latest Chilean National Health Survey (ENS 2016-17). The number of remaining teeth was classified into four groups: functional dentition (≥ 20 remaining teeth), moderate tooth loss (10 to 19), severe tooth loss (1 to 9), and edentulism (0). MM was defined based on the number of chronic conditions as a binary variable (MM≥ 2) and as a 4-level categorical variable (MMG0-G3), G0: none, G1: 1, G2: 2-4, and G3: ≥5 conditions. Stratified analysis by age group (< 65, ≥ 65 years) was performed. Mean and SD were calculated for crude and adjusted remaining teeth. Significance level was set to 0.05. Prevalence ratios were estimated with Poisson regression models with robust variance, crude and adjusted for sex, age, geographic area, and educational level. Logistic regressions models were fitted to calculate odds ratios as a sensitivity analysis.
RESULTS: Of 4,151 adults aged 17-98, 54.9% had MM and the prevalence of moderate, severe tooth loss and edentulism was 25.4%, 6.9% and 4.8% respectively. Adults aged ≥ 65 years with MM≥ 2 were 1.66 [1.04-2.66] times more likely to have severe tooth loss than those without MM. Adults aged < 65 years with MMG3 were 1.76 [1.12-2.77] times more likely to have moderate tooth loss and 2.55 [1.02-6.36] times more likely to have severe tooth loss than those without MM.
CONCLUSIONS: In this study, we found statistically significant associations between the number of chronic conditions and moderate/severe tooth loss in both analyzed age groups. These findings highlight the need to provide oral health care for adults with multimorbidity using a person-centred model and to seek strategies to prioritize health care.
Defatted cottonseed meal (CSM), the residue of cottonseeds after oil extraction, is a major byproduct of the cotton industry. Converting CSM to biochar and utilizing the goods in agricultural and environmental applications may be a value-added, sustainable approach to recycling this byproduct. In this study, raw CSM was transformed into biochar via complete batch slow pyrolysis at 300, 350, 400, 450, 500, 550, and 600 °C. Thermochemical transformation of phosphorus (P) in CSM during pyrolysis was explored. Fractionation, lability, and potential bioavailability of total P (TP) in CSM-derived biochars were evaluated using sequential and batch chemical extraction techniques. The recovery of feed P in biochar was nearly 100% at ≤550 °C and was reduced to <88% at 600 °C. During pyrolysis, the organic P (OP) molecules predominant in CSM were transformed into inorganic P (IP) forms, first to polyphosphates and subsequently to orthophosphates as promoted by a higher pyrolysis temperature. Conversion to biochar greatly reduced the mobility, lability, and bioavailability of TP in CSM. The biochar TP consisted of 9.3-17.9% of readily labile (water-extractable) P, 10.3-24.1% of generally labile (sequentially NaHCO3-extractable) P, 0.5-2.8% of moderately labile (sequentially NaOH-extractable) P, 17.0-53.8% of low labile (sequentially HCl-extractable) P, and 17.8-47.5% of residual (unextractable) P. Mehlich-3 and 1 M HCl were effective batch extraction reagents for estimating the "readily to mid-term" available and the "overall" available P pools of CSM-derived biochars, respectively. The biochar generated at 450 °C exhibited the lowest proportions of readily labile P and residual P compounds, suggesting 450 °C as the optimal pyrolysis temperature to convert CSM to biochar with maximal P bioavailability and minimal runoff risk.
This phase I, randomized, placebo-controlled, trial will evaluate the safety and feasibility of allo-MSCs administered by transendocardial injection in thirty-seven subjects with anthracycline-induced cardiomyopathy (AIC). The first six subjects received allo-MSC therapy (open label) and were assessed for safety and feasibility of the study procedures. Following 1 month data review of each of the six subjects by the National Heart, Lung, and Blood Institute Gene and Cell Therapy Data Safety Monitoring Board; this was followed by a randomized, double-blind clinical trial enrolling thirty-one subjects. These subjects were randomized 1:1 to receive allo-MSCs or placebo. All subjects underwent cardiac catheterization and study product administration using the NOGA Myostar catheter injection system. Subjects are being followed at 1 day, 1 week, 1 month, 6 months, and 12 months post study product injection. All endpoints are assessed at the 6 and 12 month visits which will occur 180 ±30 days and 365 ±30 days, respectively, after the day of study product injection (Day 0). For the purpose of the safety evaluations and endpoint analysis, the Investigators will utilize an "intention-to-treat" study population. In addition, because this phase I study is the first cell therapy study in this population, at 12 months available standard-of-care medical records for cancer surveillance will be reviewed for cancer recurrence.
Children between 4-18 years, living in the Netherlands. Besides inclusion from the general population, childhood expertise centres will contact their patients to pay attention to this study.
The study will be conducted as a Phase I prospective, randomized study in healthy adult subjects at a single center. Adult subjects age 18 to 47 years and meeting all enrollment criteria will choose to participate as subjects who receive unadjuvanted or adjuvanted H7H9 pIIV vaccine followed by a live vaccine boost at 4 weeks (Group 1, n=24), 12 weeks (Group 2, n=24), or 24 weeks (Group 3, n=24), or to be in an observational group (Group 4, n=16) which will not be scheduled for a booster dose but may serve as a roll-over group for subjects who withdraw prior to the second vaccination but agree to remain in follow-up. Within each group, subjects will be randomized at a 1:1 ratio to receive a single dose of either unadjuvanted H7N9 pIIV at 15 mcg (Subgroup A), or the same vaccine adjuvanted with the oil-in-water emulsion, MF59, (Subgroup B) delivered intramuscularly. Finally, a fifth group (Group 5, n=12) will receive two intramuscular doses of adjuvanted H7N9 pIIV separated by four weeks. The total duration of study participation for all subjects will be approximately 13 months. Recruitment, enrollment and administration of study product will be suspended when one of the following occurs in the clinical or research laboratory at the clinical site: at least two respiratory cultures or PCR assays are determined to be positive for influenza or at least 10% diagnostic tests (rapid tests, respiratory cultures or PCR assays) performed for influenza as positive during two consecutive weeks in the clinical or research laboratory at the clinical site. Recruitment, enrollment and administration of study product may be resumed after 2 weeks without a signal that influenza is still circulating in the community, as defined by the same measures that indicate the start of influenza season (i.e., less than 2 respiratory cultures or PCR assays are determined to positive for influenza or less than 10% of diagnostic tests performed or influenza with positive results). The primary objectives of this study are to (1) assess the safety of H7N9 pLAIV administered to individuals who have previously received MF59-adjuvanted or unadjuvanted H7N9 pIIV, (2) evaluate the ability of a single dose of unadjuvanted H7N9 pIIV to prime for enhanced immunogenicity (booster response) to subsequent administration of antigenically-matched H7N9 pLAIV vaccine, and to (3) evaluate the ability of a single dose of MF59-adjuvanted H7N9 pIIV to prime for enhanced immunogenicity (booster response) to subsequent administration of antigenically-matched H7N9 pLAIV vaccine. The secondary objectives of this study are to (1) assess the safety of priming with MF59-adjuvanted H7N9 pIIV or unadjuvanted H7N9 pIIV, (2) assess the immune response in subjects vaccinated with a single dose of MF59-adjuvanted H7N9 pIIV or a single dose of unadjuvanted H7N9 pIIV, and to (3) compare the booster effect seen after intervals of 4 weeks, 12 weeks, or 24 weeks within each priming group.
Herein are described processes for the preparation of a cannabinoid adjunct. The process includes contacting a first plant matter having a first cannabinoid to terpene (C/T) ratio with a solvent at a temperature below about 0 °C for at least 1 hour producing a first solvent fraction. The first solvent fraction is separated from the first plant matter and fractionated providing a second solvent fraction, a terpene fraction and a solvent-free cannabinoid fraction. The cannabinoid fraction has a second C/T ratio that is greater than or equal to the first C/T ratio. The cannabinoid fraction can be combined with a soluble fiber thereby producing the cannabinoid adjunct. The cannabinoid adjunct is suitable for use in edible products.
The drug-eluting stents (DESs) are currently used in the majority of percutaneous coronary intervention (PCI) procedures. On the other hand, the problems of the first-generation DES (late adverse events, such as very late stent thrombosis) have been pointed out. Dual antiplatelet therapy (DAPT) has become a standard regimen after DES implantation and for fear of very late stent thrombosis, DAPT is frequently performed for 1 year or longer in clinical practice. However, serious hemorrhagic complications associated with a prolonged DAPT duration can bring disadvantages to patients, and it is extremely important to clarify an optimal DAPT duration after DES procedure. Currently, 1-month DAPT regimen after bare metal stent (BMS) implantation is commonly used in clinical practice, producing no major problems. Based on a meta-analysis of recent clinical studies, it has also been reported that the use of Cobalt-Chromium Everolimus-Eluting Stent (CoCr-EES) reduces the risk of early stent thrombosis by half compared to the use of BMS. There is no necessity to extend antiplatelet therapy after CoCr-EES implantation longer than after BMS implantation, and it is considered possible to use the same 1-month DAPT duration as after BMS implantation. The investigators therefore planned a multicenter, randomized, open-label, controlled study, in which the subjects who have undergone CoCr-EES procedure will be divided into the 1-month DAPT and clopidogrel monotherapy group and the 12-month DAPT and aspirin monotherapy group. Primary endpoint is the incidence of composite events including cardiovascular death, myocardial infarction, stent thrombosis, stroke, and bleeding defined by TIMI major or minor bleeding. At first, the non-inferiority about primary endpoint of 1-month DAPT group will be evaluated at 12 months after index procedure and secondarily, the superiority about primary endpoint of 1-month DAPT group will be evaluated at 5 years after index procedure.
Individuals with a body mass index (BMI)≥25 kg/m2 are less likely to initiate and continue breastfeeding than are those with BMIs<25. Given the intergenerational health benefits of breastfeeding, it is important to understand breastfeeding behaviors and their correlates among individuals with BMIs≥25. Thus, in an observational cohort with BMI≥25 (N = 237), we aimed to characterize longitudinal relationships among breastfeeding planning, initiation, and duration and their sociodemographic/clinical correlates and determine if pre-pregnancy BMI predicts breastfeeding planning, initiation, and duration. Breastfeeding behaviors, weight/BMI, and sociodemographic/clinical characteristics were assessed in early, mid, and late pregnancy, and at six-months postpartum. Most participants planned to (84%) and initiated (81%) breastfeeding, of which 37% breastfed for ≥6 months. Participants who were married, first-time parents, higher in education/income, and had never smoked tobacco were more likely to plan, initiate, and achieve ≥6 months of breastfeeding. Higher pre-pregnancy BMI was not associated with breastfeeding planning or initiation but was associated with lower adjusted odds of breastfeeding for ≥6 months relative to <6 months. Findings suggest that support aimed at extending breastfeeding among those with elevated pre-pregnancy BMI may be warranted. Future interventions should also address sociodemographic and clinical inequities in breastfeeding.
In one embodiment, an apparatus for generating an inspection report is provided which is configured to perform certain tasks. Input from a user for an inspection report and displaying contents of the inspection report which currently has been inputted, is received. One or more context features from one of the displayed contents is identified, in a real time manner. inspection data for the object based on one or more of the identified context features is processed. A list of items of the processed inspection data is caused to be displayed, upon detection of a specific user input, to be selected by the user. And, when an item in the list is selected by the user, processed inspection data corresponding to the selected item, is inserted into the inspection report. In some embodiments, the one of the displayed contents includes keywords relating to at least one of a body region, a part of the object, anatomical structure of the object, and a pathological structure of the object.
Patients were treated with remibrutinib 25 mg bis in die/twice a day (b.i.d.). LOU064 open-label treatment taken orally for 52 weeks.
The present invention discloses a cefetamet double-function esterification precursor medicine compound and an oral preparation thereof. The chemical name of the medicine compound is (6R, 7R)-3-methyl-7-[(2-(S)-(alanyl amino-4-thiazole)-(methoxyimino) acetamido]-8-oxo-5-thio-1-azabicyclo [4, 2, 0]Zi-2-alkenyl-2-formic trimethyl acetoxyl methyl ester hydrochloride. The structure general formula and various oral preparations of the cefetamet double-function esterification precursor medicine compound are simultaneously given. The water solubility of the medicine compound of the present invention is effectively enhanced, and the absorption speed is high, and the blood medicine concentration is high. The biological availability of the oral preparation is obviously superior to the biological availability of cefetamet hydrochloride, and the oral preparation has strong antibacterial activity of high efficiency. Simultaneously, the sweetness is obviously enhanced, and various oral preparations can be developed. The oral preparation is especially suitable for children and patients with dysphagia to administer, and the application range of the oral solid preparation of the present invention is expanded.
Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. Exact incidence figures are not available. The most frequent adverse reactions to topical ocular tobramycin (TOBREX® tobramycin ophthalmic ointment) are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than 4% of patients. Similar reactions may occur with the topical use of other aminoglycoside antibiotics. Other adverse reactions have not been reported; however, if topical ocular tobramycin is administered concomitantly with systemic aminoglycoside antibiotics, care should be taken to monitor the total serum concentration. The reactions due to the steroid component are: elevation of intraocular pressure (IOP) with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing.
Rheumatoid arthritis(RA) is a chronic and progressive autoimmune disease characterized by synovial hyperplasia and joint damage leading to clinically significant functional impairment. In RA, for some unknown reason, immune cells infiltrate into synovium of joint and produce the 'rheumatoid factor', prostaglandins, cytokines and other mediators. It damages joint and cartilage, even other organs. 80% of the RA patients have Rheumatoid factor which is caused by high expression ratio of auto-antibodies in blood. Produced immune complexes, immune cells and antigen-presenting cells(including macrophages, B cells, dendritic cells) activate and release cytokines and then synovial tissue becomes thickened and damaged.

It has been reported that synthetic DMARDs(disease-modifying antirheumatic drugs) including methotrexate(MTX), sulfasalazine and biological DMARDs such as tumor necrosis factors(TNF)-α blockers, abatacept and rituximab, often in combination with MTX, are effective. But they still are limited by lack or loss of efficacy in certain patients and serious complications such as serious infections and malignancies. So, there is a need to identify new treatment.

FURESTEM-RA Inj. is composed of allogeneic hUCB-MSC(human Umbilical Cord Blood derived-Mesenchymal Stem cell). hUCB-MSCs are mesenchymal stem cells from umbilical cord blood. Mesenchymal stem cells are well-known for immunosuppression, anti-inflammatory ability and capable of differentiating into a wide range of cell types including osteocytes and chondrocytes. Therefore, FURESTEM-RA Inj. has huge possibility as cell therapy products for RA patients.